Last reviewed · How we verify
Meningococcal (vaccine) — Competitive Intelligence Brief
marketed
Bacterial polysaccharide conjugate vaccine
Neisseria meningitidis capsular polysaccharides and outer membrane proteins
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Meningococcal (vaccine) (Meningococcal (vaccine)) — GlaxoSmithKline. The meningococcal vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis, preventing meningococcal disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Meningococcal (vaccine) TARGET | Meningococcal (vaccine) | GlaxoSmithKline | marketed | Bacterial polysaccharide conjugate vaccine | Neisseria meningitidis capsular polysaccharides and outer membrane proteins |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Bacterial polysaccharide conjugate vaccine class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Meningococcal (vaccine) CI watch — RSS
- Meningococcal (vaccine) CI watch — Atom
- Meningococcal (vaccine) CI watch — JSON
- Meningococcal (vaccine) alone — RSS
- Whole Bacterial polysaccharide conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). Meningococcal (vaccine) — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab